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Accumulating evidence suggests that Japanese herbal medicines, called Kampo, have
beneficial effects on cancer chemotherapy-induced side effects. Rikkunshito ameliorates
cisplatin-induced anorexia through an antagonistic effect on the 5-HT receptors and by
increasing the serum ghrelin levels. Hangeshashinto improves irinotecan-induced diarrhea
and chemotherapy-induced mucositis by inhibiting the activity of β-glucuronidase as
well as the synthesis of prostaglandin E2. Goshajinkigan prevents oxaliplatin-induced
neurotoxicity, possibly through suppressing functional alterations of the transient receptor
potential channels. In this review, we will summarize the currently available literature
regarding the clinical efficacy and potential mechanisms of Kampo medicines in the
treatment of cancer chemotherapy-induced side effects.
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INTRODUCTION
Cancer is a major public health problem in most developed
countries; however, there have been notable improvements in the
survival rate of patients over the past three decades owing to
early detection and progress in medical treatment (DeSantis et al.,
2014; Siegel et al., 2014). A substantial number of patients with
cancer receive chemotherapy or chemoradiotherapy and benefit
from treatment with anticancer drugs (DeSantis et al., 2014).
However, because of their toxic effects on normal cells/tissues,
anticancer drugs cause many side effects with a variety of symp-
toms, such as nausea, vomiting, anorexia, diarrhea, oral mucosi-
tis, and numbness. These side effects often compromise patients’
quality of life (QOL) and sometimes make it difficult to con-
tinue chemotherapy or chemoradiotherapy (Akin et al., 2010).
Although many valuable strategies have been developed to treat
or prevent these side effects, they are still insufficient (Gibson
et al., 2013; McGuire et al., 2013; Hershman et al., 2014; Jordan
et al., 2014). Therefore, an alternative or novel approach to treat
or prevent these side effects is required.
Japanese traditional herbal medicines, called Kampo, were
imported from China 1,500 years ago and developed indepen-
dently (Motoo et al., 2011). Kampo medicines are currently
prescribed by more than 80% of medical doctors in Japan and
are covered by National Health Insurance. In recent years, several
Kampo medicines have been investigated using animal models
and clinical trials to assess their effects on chemotherapy-induced
side effects. In this review, we describe the current status of
several Kampo medicines in the treatment or prevention of
chemotherapy-induced side effects as well as their underlying
mechanisms.
RIKKUNSHITO FOR THE TREATMENT OF
CISPLATIN-INDUCED ANOREXIA
CISPLATIN-INDUCED ANOREXIA
It is important to prevent and treat chemotherapy-induced side-
effects such as anorexia, nausea, and vomiting to maintain
patients’ QOL and to continue chemotherapy safely (Hesketh,
2008). Nausea and vomiting are caused by activation of vagal
afferent neurons through the release of 5-HT and substance P
from the enterochromaffin cells in the gut via 5-HT3 and neu-
rokinin (NK)-1 receptors, respectively. Antagonists of 5-HT3 and
NK-1 receptors have been developed and are widely used for the
treatment of chemotherapy-induced nausea and vomiting (Roila
et al., 2010; Basch et al., 2012). On the other hand, anorexia
has been reported to be associated with other 5-HT receptors;
5-HT2R or 5-HT3R antagonists are associated with a decrease
in food intake, leading to anorexia, as concluded from animal
experiments (De Vry and Schreiber, 2000; Hayashi et al., 2005). 5-
HT2CR is expressed mainly in the stomach (Wouters et al., 2007),
whereas 5-HT2BR expression is restricted to the central nervous
system (Giorgetti and Tecott, 2004).
International guidelines for antiemetic use have recommended
antagonists for 5-HT3 and NK-1 receptors as well as corticos-
teroids for patients undergoing treatment with anticancer drugs
including cisplatin (Roila et al., 2010; Basch et al., 2012). However,
the effect of this treatment is still insufficient, because the com-
plete response rate and complete control rate have been reported
to be 40–75%, and anorexia as an adverse event was reported
in approximately 15% of patients (Hesketh et al., 2003; Poli-
Bigelli et al., 2003; Schmoll et al., 2006). In addition, food intake
decreased to 25% of baseline by 7 days after administration of
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chemotherapy including cisplatin (Hiura et al., 2012b). These
results suggest that gastrointestinal symptoms such as nausea,
vomiting, and anorexia following chemotherapy persist for sev-
eral days in many patients.
Ghrelin is a GH-releasing peptide isolated from the stom-
ach as an endogenous ligand for GH secretagogue receptor 1a
(GHS-R1a; Howard et al., 1996), a G-protein-coupled orphan
receptor (Kojima et al., 1999). Ghrelin has 28 amino acids, with
3Ser acylated with an n-octanoyl residue, and this octanoylation
is essential for the activation of ghrelin. Ghrelin is predominantly
produced by the endocrine X/A-like cells of the stomach (Date
et al., 2000) and plays various physiological roles as a circulating
hormone, such as inducing GH release and food intake. More
than 90% of circulating ghrelin is in an inactive form called
desacylghrelin; however, recent studies have demonstrated that
this desacylghrelin is also physiologically active (Baldanzi et al.,
2002; Bedendi et al., 2003; Tsubota et al., 2005). Administration of
ghrelin into the brain ventricles or veins of rodents induced food
intake and weight gain (Nakazato et al., 2001). The hypothalamus
has an arcuate nucleus that manages food intake, and certain food
intake-stimulating neurons produce neuropeptide Y (NPY) and
agouti-related protein (AgRP). The ghrelin receptor is expressed
in the same neurons and is thus considered to stimulate food
intake by activating the NPY/AgRP neurons (Nakazato et al.,
2001). Ghrelin secreted from the stomach binds to the ghrelin
receptor, which is produced in vagal afferent neurons and trans-
ported to the terminal of the afferent fiber, and inhibits electrical
activity of the vagal afferent fiber. This signal is transmitted to the
solitary nucleus in the medulla oblongata and then to the NPY
and growth hormone releasing hormone (GHRH) neurons in the
hypothalamus, leading to food intake and secretion of GH (Date
et al., 2002). Recent studies have demonstrated that the blood
level of ghrelin decreases after chemotherapy including cisplatin
in animals as well as in humans (Takeda et al., 2008; Ohno et al.,
2011; Hiura et al., 2012a). Therefore, ghrelin may be involved in
cisplatin-induced anorexia.
EFFECT OF RIKKUNSHITO ON CISPLATIN-INDUCED ANOREXIA
Rikkunshito is composed of 8 herbal medicines and is widely
used in Japan to treat various gastrointestinal disorders (Tat-
suta and Iishi, 1993; Yagi et al., 2004). Through animal exper-
iments, we demonstrated the following: (1) cisplatin decreases
serum ghrelin levels; (2) antagonists for the 5-HT2B or 5-HT2C
receptors recover the decrease in serum ghrelin levels and food
intake caused by cisplatin, respectively; (3) rikkunshito recovers
the decrease in serum ghrelin levels and food intake caused by
cisplatin; and (4) the flavonoids present in rikkunshito have an
antagonistic effect on the 5-HT2B and 5-HT2C receptors (Takeda
et al., 2008). Yakabi et al. (2010a,b) demonstrated that cisplatin
decreases the expression of GHS-R1a and secretion of ghrelin
in the hypothalamus via the 5-HT2C receptor, and rikkunshito
ameliorates this effect. It has also been reported that rikkunshito
antagonizes the 5-HT3 receptor (Tominaga et al., 2009).
Several clinical trials have been conducted to investigate
the effect of rikkunshito on chemotherapy-induced anorexia.
Ohno et al. (2011) performed a cross-over clinical trial using
rikkunshito involving 10 patients with unresectable or recurrent
gastric cancer treated with S-1 and cisplatin. They reported
that rikkunshito attenuated the decrease in plasma acyl ghre-
lin levels, increased food intake during chemotherapy, and
reduced the degree of anorexia caused by chemotherapy. Seike
et al. (2011) evaluated the effect of rikkunshito in 19 patients
with advanced esophageal cancer treated with docetaxel, 5-
FU, and cisplatin. They reported that rikkunshito ameliorated
chemotherapy-induced nausea and vomiting and improved the
QOL score, particularly for mood and daily activity.
HANGESHASHINTO FOR THE TREATMENT OF IRINOTECAN
HYDROCHLORIDE (CPT-11)-INDUCED DIARRHEA
CPT-11-INDUCED DIARRHEA
CPT-11 exerts an inhibitory effect on nucleic acid synthesis by
inhibition of topoisomerase I and is widely used for the treatment
of a variety of cancers (Rosen, 1998). One of the dose-limiting
toxicities is late onset diarrhea (beginning more than 24 h after
infusion) that leads to dehydration and electrolyte imbalance,
making it a life-threatening condition (Abigerges et al., 1995). The
underlying mechanism for CPT-11-induced late onset diarrhea
involves direct damage to the intestinal mucosa induced by SN-
38, a metabolite of CPT-11 (Hecht, 1998). CPT-11 is converted
to SN-38, an active form of CPT-11 in the liver, and subsequently
conjugates to inactive, non-toxic SN-38 glucuronide. Thereafter,
SN-38 glucuronide is deglucuronidated to SN-38 by bacterial β-
glucuronidase and induces mucosal damage and toxicity (Atsumi
et al., 1991).
EFFECT OF HANGESHASHINTO ON CPT-11-INDUCED DIARRHEA
Hangeshashinto is composed of seven herbs and is often used
in Japan to treat diarrhea and acute gastroenteritis (Kase et al.,
1997). Hangeshashinto is known to slow the enterohepatic cir-
culation of SN-38. Baicalin in hangeshashinto has been shown
to inhibit the activity of β-glucuronidase as well as the synthesis
of prostaglandin E2 (Narita et al., 1993; Kase et al., 1997). In
an animal experiment, hangeshashinto, and baicalin exhibited
protective effects against intestinal toxicity caused by CPT-11
(Takasuna et al., 1995). A randomized controlled trial was per-
formed involving 41 patients with non-small cell lung cancer
treated with cisplatin and CPT-11, and the grade of diarrhea
significantly improved after treatment with hangeshashinto (Mori
et al., 2003). In addition, hangeshashinto significantly reduced
the frequency of severe diarrhea (grade 3 or 4). Furthermore,
the frequency of diarrhea was less than that reported previously
(Komatsu et al., 2010). Only 1 out of 15 patients who received
125 mg/m2 of CPT-11 suffered from grade 3 diarrhea.
HANGESHASHINTO FOR THE TREATMENT OF
CHEMOTHERAPY-INDUCED ORAL MUCOSITIS
CHEMOTHERAPY-INDUCED ORAL MUCOSITIS
Oral mucositis is a common complication of chemotherapy,
affecting 18–40% of patients after the first chemotherapy cycle
(Lopez-Castano et al., 2005). The morbidity of oral mucositis is
primarily due to the pain associated with oral mucosal inflamma-
tion and ulceration, which affects food intake, oral hygiene, and
QOL (Campos et al., 2014).
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EFFECT OF HANGESHASHINTO ON CHEMOTHERAPY-INDUCED ORAL
MUCOSITIS
Hangeshashinto contains several prostaglandin E2-regulating
ingredients (Kase et al., 1998; Kono et al., 2014). In a retrospec-
tive study with a small number of patients (N = 14), topical
application of hangeshashinto improved oral mucositis (Kono,
2010). Aoyama et al. (2014) conducted a double-blind, placebo-
controlled, randomized phase II study of hangeshashinto for
oral mucositis induced by gastric cancer chemotherapy. Although
hangeshashinto did not reduce the incidence of≥2 oral mucositis,
it tended to reduce the risk of oral mucositis in the patients who
developed grade 1 oral mucositis. Yamashita et al. (2015) inves-
tigated the effect of hangeshashinto for chemoradiation-induced
mucositis in head and neck cancer patients, and hangeshashito
was associated with a significantly improved rate of completion of
chemoradiation with cisplatin. In addition, serum albumin level
was significantly maintained better in the hangeshashinto group
than in the control group. Matsuda et al. (2013) are currently con-
ducting a double-blind, placebo-controlled, randomized phase II
study of hangeshashinto for oral mucositis induced by fluorinated
pyrimidine-based colorectal cancer chemotherapy.
GOSHAJINKIGAN FOR THE TREATMENT OF
OXALIPLATIN-INDUCED NEUROTOXICITY
OXALIPLATIN-INDUCED NEUROTOXICITY
Oxaliplatin, a platinum compound, is widely used for the treat-
ment of various cancers, mainly colorectal cancer. However,
oxaliplatin-induced neurotoxicity is the most common dose-
limiting side effect (André et al., 2004; Haller et al., 2011).
Although the underlying mechanism of oxaliplatin-induced neu-
rotoxicity is not fully understood, it has been suggested that
oxaliplatin accumulates in the dorsal root ganglia and produces
axonal hyperexcitability and repetitive discharges due to changes
in voltage-dependent sodium channels (Pasetto et al., 2006; Faber
et al., 2012).
EFFECT OF GOSHAJINKIGAN ON OXALIPLATIN-INDUCED
NEUROTOXICITY
Goshajinkigan is composed of 10 herbal medicines and is widely
used in Japan for the treatment of rhigosis, numbness or pain in
the extremities, low back pain, and diabetic neuropathy (Tawata
et al., 1994; Uno et al., 2005). Animal experiments have demon-
strated that goshajinkigan prevents oxaliplatin-induced acute
peripheral neuropathy without affecting its anti-tumor efficacy
(Ushio et al., 2012) by suppressing functional alterations of the
transient receptor potential (TRP) channels, particularly TRPA1
and TRPM8 (Kato et al., 2014; Mizuno et al., 2014). Retrospective
studies and randomized controlled trials with a small number
of patients have demonstrated that goshajinkigan significantly
reduces the incidence of neurotoxicity, prolongs the duration
of oxaliplatin treatment, and delays the time to the onset of
neurotoxicity (Kono et al., 2011; Nishioka et al., 2011; Hosokawa
et al., 2012). A placebo-controlled, double-blind randomized
phase II study was conducted in patients with advanced or recur-
rent colorectal cancer treated with standard FOLFOX regimens;
goshajinkigan appeared to have an acceptable safety margin and
a promising effect in delaying the onset of grade ≥2 neurotox-
icity without impairing FOLFOX efficacy (Kono et al., 2013).
Yoshida et al. (2013) evaluated the efficacy of goshajinkigan for
oxaliplatin-induced neuropathy in patients with colorectal cancer
and demonstrated that goshajinkigan prevented exacerbation of
neuropathy.
CONCLUSION
Growing evidence suggests that Kampo medicines appear to
have beneficial effects for the treatment or prevention of sev-
eral chemotherapy-induced side effects. Because each Kampo
medicine is not composed of a single substance, further basic
studies should clarify which of the substances are responsible
for the beneficial effects as well as the underlying mechanism of
action. Although it is sometimes difficult to set appropriate and
subjective endpoints for Kampo medicines, placebo-controlled,
double-blind, randomized clinical trials similar to those for
Western medicine will provide decisive evidence.
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